Point72 Asset Management’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Point72 Asset Management’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-36,991	Closed	-$1.87M	–	1232
2020 Q3	$1.87M	Buy	+36,991	New	+$1.66M	0.01%	714
2020 Q1	–	Sell	-181,200	Closed	-$10.4M	–	1208
2019 Q4	$10.4M	Buy	181,200 +14,700	+9%	+$728K	0.05%	371
2019 Q3	$5.99M	Buy	+166,500	New	+$6.5M	0.04%	429
2019 Q1	–	Sell	-52,000	Closed	-$716K	–	1320
2018 Q4	$716K	Buy	52,000 +29,624	+132%	+$374K	﹤0.01%	845
2018 Q3	$223K	Sell	22,376 -179,404	-89%	-$2.95M	﹤0.01%	955
2018 Q2	$4.1M	Buy	+201,780	New	+$4.23M	0.02%	650

Other funds holding EIDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Point72 Asset Management's EIDX Position: Q4 2020 in Review

Point72 Asset Management sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q4 2020, closing a stake of 36,991 shares — an estimated $1.87M sold.

Point72 Asset Management first reported a position in EIDX in Q2 2018 and held it in 6 quarters. The position peaked at $10.4M in Q4 2019. 121 funds tracked by Wall St. Rank hold EIDX as of Q4 2020.

Point72 Asset Management reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
Point72 Asset Management sold 36,991 Eidos Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $1.87M.
Point72 Asset Management first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2018 and held it in 6 quarters.
Point72 Asset Management's Eidos Therapeutics, Inc. Common Stock position peaked at $10.4M in Q4 2019.
121 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Point72 Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.